Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.85 |
| ▸ | SYK | P43405 | 2/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | IGF1R | P08069 | 1/20 | 0.65 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.65 |
| ▸ | BMX | P51813 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694510 | 1.00 | AURKA (0.85) | AURKASYKLCKIGF1REIF2AK2 | |
| SCHEMBL653992 | 0.88 | SYK (0.68) | AURKASYK | |
| SCHEMBL654448 | 0.84 | AURKA (0.67) | AURKASYKLCKIGF1REIF2AK2 | |
| SCHEMBL20927073 | 0.84 | AURKA (0.73) | AURKASYKMAPK8KDM4E | |
| SCHEMBL25336406 | 0.83 | CAMK2D (0.69) | AURKASYKKDM4E | |
| SCHEMBL30554563 | 0.83 | CAMK2D (0.69) | AURKASYKKDM4E | |
| SCHEMBL29655511 | 0.83 | AURKA (0.72) | AURKASYKLCKIGF1REIF2AK2 | |
| SCHEMBL4237476 | 0.82 | AURKA (1.00) | AURKASYKLCKIGF1REIF2AK2 | |
| SCHEMBL3694508 | 0.82 | AURKA (1.00) | AURKASYKLCKIGF1REIF2AK2 | |
| SCHEMBL13166084 | 0.81 | TNNI3K (0.63) | AURKASYKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | claimed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | claimed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | claimed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | AURKA 43/4885SYK 17/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.